+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients



Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients



Transfusion 31(2): 122-128



A prospective phase II trial was conducted to assess the feasibility, tolerance, and efficacy of a device designed for selective removal of rheumatoid factor from the plasma of rheumatoid arthritis patients. The device contained terpolymer hydrogel-coated plates with chemically attached, aggregated human immunoglobulin G, and it operated as an immunoaffinity column. Sixty-one patients aged 25 to 73 underwent weekly plasmapheresis treatments (the primary therapy phase). During the trial, patients continued current rheumatoid arthritis medications without dose adjustments. All patients received two to six treatments (primary therapy). Responding patients were eligible to continue apheresis treatment every 2 to 6 weeks (maintenance therapy). No serious, untoward side effects were noted in the course of this study; of 640 treatments, only 2 (in different patients) were aborted, one because of complaints of dizziness and angioedema and the other because of chest tightness and shortness of breath. Except for a significant (p < 0.05) decrease in serum iron, no significant changes in complete blood count, serum electrolytes, renal and hepatic function tests, or serum C3 and C4 were noted. Although the trial was not designed to determine clinical efficacy, patients noted less morning stiffness, longer time to onset of fatigue, and improved global pain assessment (p < 0.004); significant objective improvements were noted in joint pain, tenderness, swelling, and the number of affected joints (p < 0.001). One-half of the treated patients had at least a 50 percent improvement in objective measures of antirheumatic activity. Although serum rheumatoid factor could be recovered in vitro in large quantities, no correlation was noted between changes in serum rheumatoid factor concentration and clinical response. This therapeutic modality was safe, well tolerated, and associated with clinical improvement in some patients. It merits further evaluation in a prospective phase III clinical trial.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 007777656

Download citation: RISBibTeXText

PMID: 1996481

DOI: 10.1046/j.1537-2995.1991.31291142942.x


Related references

Selective infiltration of B cells committed to the production of monoreactive rheumatoid factor in synovial tissue of patients with rheumatoid arthritis. Clinical Immunology & Immunopathology 69(1): 16-22, 1993

Natural killer (NK) cells at inflammatory sites of patients with rheumatoid arthritis and IgM rheumatoid factor positive polyarticular juvenile rheumatoid arthritis. Clinical Rheumatology 6(2): 215-225, 1987

Studies on chryso therapy in rheumatoid arthritis part 3 pathogenesis of rheumatoid factor in rheumatoid arthritis and influence of gold salt on rheumatoid factor. Okayama Igakkai Zasshi 88(11-12): 1133-1148, 1976

High prevalence of rheumatoid factor in community-based series of patients with rheumatoid arthritis meeting the new (1987) ARA criteria: RF-negative non-erosive rheumatoid arthritis is very rare. Scandinavian Journal of Rheumatology 27(5): 368-372, 1998

Differential expression of a cross reactive idiotype on serum rheumatoid factor and on lymphocyte culture derived rheumatoid factor in rheumatoid arthritis patients. Arthritis & Rheumatism 29(4 SUPPL): S33, 1986

Presence of hidden rheumatoid factor hrf activity in patients with juvenile rheumatoid arthritis jra who express the major rheumatoid factor cross reactive idiotype rcri. Arthritis & Rheumatism 31(4 SUPPL): S77, 1988

Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis evidence for differential influences of therapy and clinical status on igm and iga rheumatoid factor expression. Arthritis & Rheumatism 33(8): 1156-1161, 1990

19S IgM rheumatoid factor-7S IgG rheumatoid factor immune complexes isolated in sera of patients with juvenile rheumatoid arthritis. Pediatric Research 20(10): 977-981, 1986

Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis and Rheumatism 63(1): 26-36, 2011

Therapeutic strategy and significance of serum rheumatoid factor in patients with rheumatoid arthritis during infliximab treatment. Nihon Rinsho Men'eki Gakkai Kaishi 33(3): 135-141, 2010

Is the response to anti-TNFalpha treatment influenced by the presence of IgM rheumatoid factor, in Rheumatoid Arthritis patients?. Acta Reumatologica Portuguesa 33(4): 430-434, 2009

Efficacy of rituximab treatment and further courses of treatment in patients with rheumatoid arthritis is not dependent on rheumatoid factor seroreversion. 2006

The prevalence of rheumatoid arthritis and rheumatoid factor in relatives and spouses of sero positive and sero negative patients suffering from definite or classical rheumatoid arthritis. International Congress Series : 123-127, 1968

Which antigen to use in the detection of rheumatoid factors? Comparison of patients with rheumatoid arthritis and subjects with 'false positive' rheumatoid factor reactions. Clinical and Experimental Immunology 77(3): 349-355, 1989

Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis. Southern Medical Journal 99(11): 1209-1215, 2007